NCT06692452 2026-04-01Tazemetostat Plus CHOP in 1L T-cell LymphomaDana-Farber Cancer InstitutePhase 2 Withdrawn
NCT05800366 2026-03-05A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell LymphomaDana-Farber Cancer InstitutePhase 2 Recruiting41 enrolled